Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL‐directed chemotherapy combined with continuous imatinib
Authors:
- 19 July 2016
- journal article
- case report
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 63 (12) , 2243-2245
Abstract
An 11‐year‐old male was diagnosed with chronic‐phase chronic myeloid leukemia (CML) in 1998 and received therapy with interferon‐α2b and low‐dose cytarabine. In 6 years, he progressed to lymphoid blast crisis and received induction chemotherapy with prednisolone, vincristine, daunorubicin, andl‐asparaginase concomitantly with imatinib 400 mg/day, and continuation with vincristine + prednisolone, cytarabine + etoposide, vincristine +l‐asparaginase, cyclophosphamide + etoposide, and 6‐mercaptopurine + methotrexate. Complete molecular response (MR) was achieved and therapy was continued with imatinib 800 mg/day. He relapsed to chronic‐phase CML after interruption of imatinib and regained MR after its restart. The patient is alive 17.5 years after CML diagnosis and 11.5 years after lymphoid blast crisis.Keywords
This publication has 15 references indexed in Scilit:
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia, 2016
- Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trialsThe Lancet Haematology, 2015
- CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemiaBlood, 2011
- Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 studyCancer, 2010
- Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upHaematologica, 2008
- Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous LeukemiaSeminars in Oncology, 2008
- Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1997
- Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post‐remission bone marrow transplant →— a pilot studyEuropean Journal of Haematology, 1996
- Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapyThe Lancet, 1991
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973